Innova Captab Limited

NSE: INNOVACAP · Healthcare

Innova Captab Limited Share Price & Analysis

867.5 -0.58%Updated 5 Jun 2026, 05:02 pm IST
LTP
867.5
-0.58%
Open
High
889
Low
857.05
Close
₹867.5
52W High
₹1,021
52W Low
₹608
Volume
24K
Lot Size
1
Sector
Healthcare
Market Cap
₹5K Cr
Face Value
₹10
Small Cap

Price Chart

Fundamentals

P/E
35
Sector P/E
48.9
P/B
4.54
EPS
₹23.14
ROE
13.8%
ROCE
15%
D/E Ratio
0.32
Div Yield
0.23%
Book Value
₹191
+

Strengths

  • Efficient capital deployment (ROCE 15%)
  • Attractively valued vs sector (P/E 35x vs industry 48.9x)
  • Low debt relative to equity (D/E 0.3x)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
1,783
₹4.3L Cr34.45.121620.50.07
DIVISLAB
Divi's Laboratories Limited
6,616
₹1.7L Cr66.110.4816.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
4,416
₹1.5L Cr66.417.8127.615.40.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,315
₹1.2L Cr59.512.6222.117.90.88
CIPLA
Cipla Limited
1,402
₹1.1L Cr27.33.2912.416.60.01
ZYDUSLIFE
Zydus Lifesciences Limited
1,091
₹1.1L Cr204.0521.221.20.38
DRREDDY
Dr. Reddy's Laboratories Limited
1,283
₹1.1L Cr25.42.8311.813.60.16

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

INNOVACAP · as of Mar 2026

Promoters50.90%
FII0.08%0.15
DII20.17%0.50
Public28.86%0.34
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters50.90%50.90%50.90%50.90%50.90%50.90%
FII1.19%1.01%0.74%0.35%0.23%0.08%
DII21.24%20.61%19.96%19.77%19.67%20.17%
Public26.67%27.48%28.41%29.00%29.20%28.86%

Corporate Events

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

Results6 May 2026

Interim Dividend - Rs 2 Per Share

Dividend29 Jan 2026

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹450 Cr
▲18.4%
₹380 Cr
▲8.0%
₹352 Cr
▲11.7%
₹315 Cr
▼0.3%
₹316 Cr
▼0.6%
₹318 Cr
▲8.2%
₹294 Cr
▲11.8%
₹263 Cr
Op. Profit
₹69 Cr
▲32.7%
₹52 Cr
▲0.0%
₹52 Cr
▲8.3%
₹48 Cr
▲2.1%
₹47 Cr
▼6.0%
₹50 Cr
▲19.0%
₹42 Cr
▲10.5%
₹38 Cr
OPM
15.0%
▲7.1%
14.0%
▼6.7%
15.0%
▲0.0%
15.0%
▲0.0%
15.0%
▼6.3%
16.0%
▲14.3%
14.0%
▲0.0%
14.0%
Net Profit
₹42 Cr
▲40.0%
₹30 Cr
▼3.2%
₹31 Cr
▲3.3%
₹30 Cr
▼11.8%
₹34 Cr
▼2.9%
₹35 Cr
▲20.7%
₹29 Cr
▲0.0%
₹29 Cr
EPS (₹)
7.37
▲42.3%
5.18
▼4.4%
5.42
▲4.8%
5.17
▼13.5%
5.98
▼2.3%
6.12
▲18.8%
5.15
▲2.6%
5.02

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Revenue
₹1.6K Cr
▲31.0%
₹1.2K Cr
▲15.1%
₹1.1K Cr
▲16.7%
₹926 Cr
▲15.6%
₹801 Cr
▲94.9%
₹411 Cr
▲10.2%
₹373 Cr
▲4.8%
₹356 Cr
Expenses
₹1.4K Cr
▲31.2%
₹1.1K Cr
▲14.0%
₹927 Cr
▲14.0%
₹813 Cr
▲15.5%
₹704 Cr
▲97.8%
₹356 Cr
▲10.6%
₹322 Cr
▲2.2%
₹315 Cr
Op. Profit
₹243 Cr
▲30.6%
₹186 Cr
▲20.8%
₹154 Cr
▲35.1%
₹114 Cr
▲18.8%
₹96 Cr
▲77.8%
₹54 Cr
▲5.9%
₹51 Cr
▲24.4%
₹41 Cr
OPM
15.0%
▲0.0%
15.0%
▲7.1%
14.0%
▲16.7%
12.0%
▲0.0%
12.0%
▼7.7%
13.0%
▼7.1%
14.0%
▲27.3%
11.0%
Other Income
₹7 Cr
▼41.7%
₹12 Cr
▲0.0%
₹12 Cr
▲33.3%
₹9 Cr
▲200.0%
₹3 Cr
▲200.0%
₹1 Cr
▲0.0%
₹1 Cr
₹0 Cr
Interest
₹17 Cr
▲750.0%
₹2 Cr
▼90.5%
₹21 Cr
▲5.0%
₹20 Cr
▲233.3%
₹6 Cr
▲50.0%
₹4 Cr
▼20.0%
₹5 Cr
▼16.7%
₹6 Cr
Depreciation
₹45 Cr
▲80.0%
₹25 Cr
▲56.3%
₹16 Cr
▲45.5%
₹11 Cr
▲37.5%
₹8 Cr
▲33.3%
₹6 Cr
▼40.0%
₹10 Cr
▼9.1%
₹11 Cr
PBT
₹188 Cr
▲9.9%
₹171 Cr
▲31.5%
₹130 Cr
▲41.3%
₹92 Cr
▲7.0%
₹86 Cr
▲87.0%
₹46 Cr
▲21.1%
₹38 Cr
▲52.0%
₹25 Cr
Tax %
25.0%
▲0.0%
25.0%
▼7.4%
27.0%
▲3.8%
26.0%
▲4.0%
25.0%
▼3.8%
26.0%
▲0.0%
26.0%
▲30.0%
20.0%
Net Profit
₹141 Cr
▲10.2%
₹128 Cr
▲36.2%
₹94 Cr
▲38.2%
₹68 Cr
▲6.3%
₹64 Cr
▲88.2%
₹34 Cr
▲21.4%
₹28 Cr
▲40.0%
₹20 Cr
EPS (₹)
24.63
▲9.9%
22.41
▲35.9%
16.49
▲16.5%
14.16
▼97.3%
532.92
▲85.4%
287.5
▲23.7%
232.42
▲40.3%
165.67
Div Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Sep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Liabilities
Equity Capital
₹57 Cr
▲0.0%
₹57 Cr
▲0.0%
₹57 Cr
▲0.0%
₹57 Cr
▲18.8%
₹48 Cr
▲300.0%
₹12 Cr
▲0.0%
₹12 Cr
▲0.0%
₹12 Cr
▲0.0%
₹12 Cr
Reserves
₹1.0K Cr
▲7.3%
₹964 Cr
▲6.9%
₹902 Cr
▲16.5%
₹774 Cr
▲238.0%
₹229 Cr
▲16.2%
₹197 Cr
▲48.1%
₹133 Cr
▲35.7%
₹98 Cr
▲40.0%
₹70 Cr
Borrowings
₹344 Cr
▲2.4%
₹336 Cr
▼0.6%
₹338 Cr
▲38.0%
₹245 Cr
▲3.4%
₹237 Cr
▲19.1%
₹199 Cr
▲332.6%
₹46 Cr
▼14.8%
₹54 Cr
▼25.0%
₹72 Cr
Other Liabilities
₹403 Cr
▲20.3%
₹335 Cr
▲23.6%
₹271 Cr
▲12.9%
₹240 Cr
▲25.7%
₹191 Cr
▲14.4%
₹167 Cr
▼6.7%
₹179 Cr
▲121.0%
₹81 Cr
▲19.1%
₹68 Cr
Total Liabilities
₹1.8K Cr
▲8.6%
₹1.7K Cr
▲7.9%
₹1.6K Cr
▲19.1%
₹1.3K Cr
▲86.9%
₹704 Cr
▲22.4%
₹575 Cr
▲55.4%
₹370 Cr
▲51.0%
₹245 Cr
▲9.9%
₹223 Cr
Assets
Fixed Assets
₹842 Cr
▼0.6%
₹847 Cr
▲2.0%
₹830 Cr
▲131.8%
₹358 Cr
▲95.6%
₹183 Cr
▲0.0%
₹183 Cr
▲131.6%
₹79 Cr
▲8.2%
₹73 Cr
▼6.4%
₹78 Cr
CWIP
₹16 Cr
▲128.6%
₹7 Cr
▼69.6%
₹23 Cr
▼93.3%
₹341 Cr
▲1450.0%
₹22 Cr
₹0 Cr
▼100.0%
₹7 Cr
₹0 Cr
₹0 Cr
Investments
₹41 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
Other Assets
₹939 Cr
▲12.1%
₹838 Cr
▲17.0%
₹716 Cr
▲16.0%
₹617 Cr
▲23.4%
₹500 Cr
▲27.6%
₹392 Cr
▲38.5%
₹283 Cr
▲64.5%
₹172 Cr
▲19.4%
₹144 Cr
Total Assets
₹1.8K Cr
▲8.6%
₹1.7K Cr
▲7.9%
₹1.6K Cr
▲19.1%
₹1.3K Cr
▲86.9%
₹704 Cr
▲22.4%
₹575 Cr
▲55.4%
₹370 Cr
▲51.0%
₹245 Cr
▲9.9%
₹223 Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Operating CF
₹117 Cr
▲82.8%
₹64 Cr
▼56.2%
₹146 Cr
▲117.9%
₹67 Cr
▲13.6%
₹59 Cr
▲40.5%
₹42 Cr
▲35.5%
₹31 Cr
▲63.2%
₹19 Cr
Investing CF
₹-107 Cr
▲29.6%
₹-152 Cr
▲69.5%
₹-499 Cr
▼448.4%
₹-91 Cr
▲51.6%
₹-188 Cr
▼840.0%
₹-20 Cr
▼233.3%
₹-6 Cr
▲33.3%
₹-9 Cr
Financing CF
₹-22 Cr
▼123.9%
₹92 Cr
▼74.5%
₹361 Cr
▲1237.0%
₹27 Cr
▼78.4%
₹125 Cr
▲757.9%
₹-19 Cr
▲17.4%
₹-23 Cr
▼155.6%
₹-9 Cr
Net Cash Flow
₹-12 Cr
▼400.0%
₹4 Cr
▼50.0%
₹8 Cr
▲166.7%
₹3 Cr
▲160.0%
₹-5 Cr
▼266.7%
₹3 Cr
▲200.0%
₹1 Cr
▲0.0%
₹1 Cr
Free Cash Flow
₹55 Cr
▲150.9%
₹-108 Cr
▲23.4%
₹-141 Cr
▼1181.8%
₹-11 Cr
▲47.6%
₹-21 Cr
▼191.3%
₹23 Cr
▼14.8%
₹27 Cr
▲145.5%
₹11 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Debtor Days
98d
▲1.0%
97d
▲0.0%
97d
▼6.7%
104d
▲7.2%
97d
▼21.1%
123d
▲44.7%
85d
▼8.6%
93d
Inventory Days
98d
▼17.6%
119d
▲30.8%
91d
▲18.2%
77d
▲1.3%
76d
▼29.0%
107d
▲27.4%
84d
▲68.0%
50d
Days Payable
110d
▼4.3%
115d
▲1.8%
113d
▲7.6%
105d
▲22.1%
86d
▼34.8%
132d
▲43.5%
92d
▲15.0%
80d
Cash Conv. Cycle
86d
▼14.9%
101d
▲34.7%
75d
▼2.6%
77d
▼11.5%
87d
▼12.1%
99d
▲28.6%
77d
▲20.3%
64d
Working Capital Days
95d
▲17.3%
81d
▲5.2%
77d
▲32.8%
58d
▲56.8%
37d
▼5.1%
39d
▼13.3%
45d
▲50.0%
30d
ROCE
15.0%
▲0.0%
15.0%
▼21.1%
19.0%
▼20.8%
24.0%
▼22.6%
31.0%
▲10.7%
28.0%
▲7.7%
26.0%

Source: Screener.in · Lower days = better efficiency

About Innova Captab Limited

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Healthcare · Pharmaceuticals & Biotechnology

Frequently Asked Questions

What is Innova Captab Limited share price today?
Innova Captab Limited (INNOVACAP) is currently trading at ₹867.5 on NSE, down 0.58% as of the last market session. Prices update daily after market close on MarketNetra.
Is Innova Captab Limited available in F&O (Futures & Options)?
Yes, Innova Captab Limited (INNOVACAP) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Innova Captab Limited 52-week high and low?
Innova Captab Limited's 52-week high is ₹1,021 and the 52-week low is ₹608. The current price of ₹867.5 is 15.0% below the 52W high.
What is Innova Captab Limited P/E ratio?
Innova Captab Limited's current P/E ratio is 35. This indicates the market is paying ₹35 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Innova Captab Limited options?
Innova Captab Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade INNOVACAP options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.